Leukemia Research
Volume 32, Issue 2 , Pages 251-254 , February 2008

Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients

Received 6 April 2007 ,Revised 25 May 2007 ,Accepted 28 May 2007.

References 

  1. Greenberg P, Cox C, LeBeau MM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  2. Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer. 2004;101(2):226–241
  3. Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug 28;8:791–803
  4. Bennett JM, Catovsky D, Daniel MT. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  5. WHO . A handbook for reporting results of cancer treatment. Geneva: WHO Publications; 1979;
  6. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. World Health Organization (WHO) International Working Group, Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96(12),3671–4.
  7. Soignet SL, Maslak P, Wang ZG. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339(19):1314–1318
  8. Rajkumar SV, Haymen S, Fonseca R. Thalidomide plus dexamethasone and thalidomide alone as first-line therapy for newly diagnosed myeloma. Blood. 2000;96(Suppl 1):168a

PII: S0145-2126(07)00242-1

doi: 10.1016/j.leukres.2007.05.025

Leukemia Research
Volume 32, Issue 2 , Pages 251-254 , February 2008

Article Tools